We were unable to find support for the claim that lecanemab binds a different, more soluble, human target than aducanumab and donanemab. Antibody preference for plaques vs CAA is unlikely to explain differences in ARIA-E rates. alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
INTRODUCTION
Lecanemab binds “protofibrils,” which are poorly characterized in human brain. It is unknown why lecanemab caused fewer amyloid-related imaging abnormalities (ARIAs) than other antibodi.....
